Close Menu

    Subscribe to Updates

    Get the latest creative news from Healthradar about News,Health and Gadgets.

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    What's Hot

    Trump Claims ‚No Downside‘ to Avoiding Tylenol During Pregnancy. He’s Wrong.

    25. September 2025

    Proscia® Launches Virtual Staining to Transform Digital Pathology with AI

    25. September 2025

    Willow Launches Wearable Breast Pump with App

    25. September 2025
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest Vimeo
    healthradar.nethealthradar.net
    • Home
    • Ai
    • Gadgets
    • Health
    • News
    • Contact Us
    Contact
    healthradar.nethealthradar.net
    Home»News»Abbott lowers sales forecast on diagnostics decline, US funding cuts
    News

    Abbott lowers sales forecast on diagnostics decline, US funding cuts

    HealthradarBy Healthradar17. Juli 2025Keine Kommentare3 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    Abbott lowers sales forecast on diagnostics decline, US funding cuts
    Share
    Facebook Twitter LinkedIn Pinterest Email


    This audio is auto-generated. Please let us know if you have feedback.

    By the numbers

     

    Q2 revenue: $11.14 billion

    7.4% increase year over year

     

    Medical device sales: $5.37 billion

    13.4% increase year over year

     

    Diagnostics sales: $2.17 billion

    1% decrease year over year

    Abbott lowered its sales forecast for the year, citing a drop in diagnostic testing. CEO Robert Ford told investors on Thursday that the company is seeing a drop-off in COVID-19 testing sales, challenges in China’s core laboratory market and a reduction in U.S. foreign aid funding for HIV testing, with a combined impact of more than $1 billion. 

    The company reduced its 2025 organic sales growth forecast to a range of 6% to 7%, from the previous forecast of 7.5% to 8.5% shared in the first quarter.

    “Even with that billion dollars, we’re still forecasting high single-digit growth and absorbing the impact of tariffs,” Ford said. 

    The company now expects “just under $200 million” of impact from tariffs. CFO Phil Boudreau said the amount was down from previous estimates, when the company had outlined “a few hundred million” in tariff costs.

    Discussing how the company plans to mitigate tariffs, Ford said that Abbott plans to open a new cardiovascular manufacturing facility in Georgia in 2028. 

    “Once tariffs get set in place, they’re very difficult to walk away from,” the CEO said, “so we have to think medium term, but also long term.”

    Growth in medical devices, diabetes

    A bright spot for Abbott was its medical device segment, which grew by more than 13% to $5.37 billion in sales. The company’s diabetes segment grew by more than 20% to $1.98 billion. 

    Analysts asked about Abbott’s plans for a dual analyte sensor that would provide glucose and ketone readings. The company recently showcased the device during the American Diabetes Association’s Scientific Sessions. 

    Ford declined to provide a timeline or pricing details for the planned device. BTIG analyst Marie Thibault wrote in June that Abbott’s management expects a launch sometime next year. The company is also partnering with insulin pump companies, including Tandem, Sequel Med Tech and Beta Bionics, to support the new sensor.

    “I think this is going to be a real next-level, significant change in the CGM market,” Ford said, specifically for intensive insulin users. 

    Abbott’s electrophysiology business, with the company’s new Volt pulsed field ablation device to treat cardiac arrhythmias, grew by 11.5% to $700 million.



    Source link

    Abbott cuts Decline Diagnostics forecast Funding lowers sales
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleElucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors
    Next Article Ultra-Processed Foods Directly Linked to Chronic Diseases
    ekass777x
    Healthradar
    • Website

    Related Posts

    News

    Proscia® Launches Virtual Staining to Transform Digital Pathology with AI

    25. September 2025
    News

    Cigna to Cover Cleerly’s AI-Based Cardiovascular Imaging

    25. September 2025
    News

    Medtronic expands AI, robotics hub in London; Virtuoso robot gets FDA breakthrough status

    25. September 2025
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    Garmin Venu 4: Everything we know so far about the premium smartwatch

    7. August 202566 Views

    The Top 3 Tax Mistakes High-Earning Physicians Make

    7. August 202524 Views

    Linea Expands AI-Powered Heart Failure Care Solution

    6. August 202519 Views

    Neurode wants to treat and track ADHD symptoms through a wearable headband

    1. Juni 20259 Views
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews

    Subscribe to Updates

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    About Us

    Welcome to HealthRadar.net — your trusted destination for discovering the latest innovations in digital health. We are dedicated to connecting individuals, healthcare professionals, and organizations with cutting-edge tools, applications

    Most Popular

    Garmin Venu 4: Everything we know so far about the premium smartwatch

    7. August 202566 Views

    The Top 3 Tax Mistakes High-Earning Physicians Make

    7. August 202524 Views
    USEFULL LINK
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    QUICK LINKS
    • Ai
    • Gadgets
    • Health
    • News
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    Copyright© 2025 Healthradar All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.